Novartis is expanding its production capacity in the United States, with the announcement of a new site in Morrisville, North Carolina. This plant is the seventh site as part of the Swiss pharma’s $23 billion (CHF18 million) investment plan in the US. + Get the most important news from Switzerland in your inbox The new plant will be dedicated to the production of active pharmaceutical ingredients for solid formulations (tablets, capsules) as well as for RNA-based therapies, the Basel-based pharmaceutical group said in a press release on Thursday. The 56,200-square-foot facility will bring the company’s North Carolina presence to five sites in three locations. End-to-end integrated production Since committing in April 2025 to produce all of its key medicines for US patients in the US, Novartis has made significant progress in its plans to establish end-to-end integrated manufacturing. In November 2025, a dedicated manufacturing facility for radioligand therapy was opened in Carlsbad …